[Image courtesy of Adobe Stock]
Bristol Myers Squibb
Anti-CTLA-4 NF: The oncology monoclonal antibody candidate directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) known as BMS-986218 was in Phase 2.
Anti-CTLA-4 Probody therapeutic: The CTLA-4-targeting oncology antibody was in Phase 2. Known as BMS-986249, BMS had developed the antibody in collaboration with CytomX Therapeutics.
Anti-SIRPα in solid tumors: The anti-signal regulatory protein-alpha candidate known as CC-95251 was in Phase 1.
Branebrutinib: The small-molecule covalent inhibitor of Bruton’s tyrosine kinase was in Phase 2. It is also known as BMS-986195.
Cendakimab: Bristol Myers said it would no longer develop its atopic dermatitis antibody cendakimab, which had completed a Phase 2 study. Although the study met its primary endpoint, the treatment landscape for atopic dermatitis is crowded, and cendakimab does not offer a significant advantage over these existing options, according to the company’s chief medical officer, Samit Hirawat.
IL-12 Fc: Known as DF6002 and BMS-986415 is monovalent IL-12 immunoglobulin Fc fusion protein oncology drug candidate that was in Phase 1.
MK2 inhibitor in ankylosing spondylitis: The immunology drug candidate known as CC-99677 was in Phase 2. It was profiled in Arthritis Research & Therapy.
New molecular entity: The undisclosed fibrosis drug candidate was in Phase 1.
ROR1 CAR-T: The hematology drug candidate acquired from Juno Therapeutics was in Phase 1. It was also known as JCAR-024.
STING agonist: The agonist of stimulator of interferon genes (STING) protein was in Phase 1. The oncology drug candidate was also known as BMS-986301.
GSK
GSK3915393: GSK said in a quarterly earnings call that it had pulled the plug on GSK3915393, an inhibitor of transglutaminase 2 (TG2). The company had believed GSK3915393 held potential for celiac disease. The drug’s safety, tolerability and pharmacokinetics were studied in a Phase 1.
Belantamab and GSK3878858A: The company has also pulled several other drug candidates from its pipeline, including the anti-BCMA antibody belantamab mafodotin (GSK2857916) for third-line multiple myeloma. It is also giving up GSK3878858A, a recombinant protein vaccine against S. aureus that was in a Phase 2 study.
GSK4362620A: GSK is also pulling the plug on GSK4362620A, a COVID-19 plant-derived virus-like particles vaccine known as Covifenz. GSK had been jointly developing the vaccine with Medicago but cited “major manufacturing issues” in preventing the use of the vaccine.
Janssen
JNJ-6358 and JNJ-8902: The company has decided to deprioritize the oncology bispecific JNJ-6358 and the prostate cancer candidate JNJ-8902. Neither shows up on the company’s latest overview of its pipeline. Trials for the two drug candidates, however, remain ongoing.
JNJ-6358 binds to CD3 on T-cells and human leukocyte antigen G (HLA-G) on cancer cells, while JNJ-8902 is CD3 x TMEFF2 bispecific.
Merck & Co.
Chikungunya vaccine: The company has given up on a vaccine for chikungunya, a mosquito-transmitted viral infection. Merck acquired the vaccine candidate from its 2020 acquisition of Themis Bioscience. The vaccine was studied in a Phase 2 clinical trial. Emergent Biosolutions continues to have a chikungunya vaccine candidate in development.
Lenvima glioblastoma indication: Merck also is pulling the plug on targeting glioblastoma with Lenvima (lenvatinib), which it had been testing in combination with Keytruda (pembrolizumab) as part of its LEAP program. Eisai is a collaborator in the LEAP program, which also focuses on triple-negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer, biliary tract cancers and pancreatic cancer.
Novartis
Cosentyx: Novartis said it had abandoned a Phase 3 study of Cosentyx (secukinumab), an IL-17A antibody in active peripheral spondyloarthritis. A note on clinicaltrials.gov said the trial was “terminated due to strategic decision of senior management.”
Branaplam: The company also stated in an interim 2022 earnings report that it would cull its branaplam program after reviewing the potential benefit-risk from the Phase 2 VIBRANT-HD study in adults with Huntington’s Disease. In August, Novartis hit pause on a Phase 2b study of branaplam after identifying a potential association between the drug candidate and peripheral neuropathy.
The company was also testing the drug candidate in a Phase 2 study involving patients with spinal muscular atrophy.
Pfizer
Recifercept/additional Paxlovid indications: The Big Pharma has announced it will discontinue eight programs, including recifercept for achondroplasia (dwarfism) and two indications for COVID-19 antiviral Paxlovid.
Other programs: Pfizer is also dropping a drug for autoimmune disorders that won an orphan designation for chronic inflammatory demyelinating polyneuropathy and a biologic for solid tumors. Finally, it is also pulling the plug on kinase inhibitors for melanoma and metastatic breast cancer.
Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development
